TD Asset Management
VERV

TD Asset Management’s Verve Therapeutics VERV Stock Holding History

TD Asset Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-59,856
Closed -$292K – 1431
2024
Q2 		$292K Hold
59,856
– – ﹤0.01% 1316
2024
Q1 		$795K Buy
59,856
+12,800
+27% +$170K ﹤0.01% 1218
2023
Q4 		$656K Buy
47,056
+15,994
+51% +$198K ﹤0.01% 1262
2023
Q3 		$412K Hold
31,062
– – ﹤0.01% 1300
2023
Q2 		$582K Hold
31,062
– – ﹤0.01% 1236
2023
Q1 		$448K Buy
31,062
+6,200
+25% +$121K ﹤0.01% 1282
2022
Q4 		$481K Buy
24,862
+11,320
+84% +$300K ﹤0.01% 1292
2022
Q3 		$463K Buy
+13,542
New +$432K ﹤0.01% 1309

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

TD Asset Management's VERV Position: Q3 2024 in Review

TD Asset Management sold out of Verve Therapeutics (VERV) in Q3 2024, closing a stake of 59,856 shares — an estimated $292K sold.

TD Asset Management first reported a position in VERV in Q3 2022 and held it in 8 quarters. The position peaked at $795K in Q1 2024. 174 funds tracked by Wall St. Rank hold VERV as of Q3 2024.

  • TD Asset Management reported no remaining Verve Therapeutics position as of Q3 2024 after selling out during the quarter.
  • TD Asset Management sold 59,856 Verve Therapeutics shares in Q3 2024, an estimated $292K.
  • TD Asset Management first reported a position in Verve Therapeutics in Q3 2022 and held it in 8 quarters.
  • TD Asset Management's Verve Therapeutics position peaked at $795K in Q1 2024.
  • 174 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2024.

Based on TD Asset Management's 13F filing for Q3 2024, filed 1 Nov 2024.